SingleBioregulators

Testoluten 20mg

An oral animal-derived testicular peptide extract explored in bioregulator research for male endocrine and reproductive support.

Mechanism

The preparation is hypothesized to deliver short, tissue-homologous peptide sequences that modulate gene expression and protein synthesis within testicular target tissues, including Leydig and germinal cells.

Dosing

Standard research protocols document an introductory oral dose of 20 mg (1 capsule) daily.

Reconstitution

As an encapsulated oral preparation, this agent requires no bacteriostatic water or liquid reconstitution.

Storage

Store sealed capsules in a dry, dark environment maintained at controlled room temperature.

Mix & measure Testoluten 20mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Testoluten 20mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration—

Draw volume—

On the syringe—

Total doses in vial: —

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Initial Phase (Days 1–10)	20 mg (1 capsule) once daily	Oral capsule (N/A)
Intensive Phase (Days 11–30)	40 mg (2 capsules) once daily	Oral capsule (N/A)
Maintenance Phase	20–40 mg daily for 10–30 days (repeat 2–3x/year)	Oral capsule (N/A)

Reconstitution Steps

1
Verify the intact packaging and documented milligram strength of each Testoluten capsule.
2
Do not attempt reconstitution, dissolution, or aqueous extraction with bacteriostatic water, as the product is pre-measured for oral study.
3
Prepare the required oral dose with a measured volume of purified water.
4
Administer the capsule whole, typically documented approximately 15 to 20 minutes prior to a meal.
5
Reseal the original capsule container immediately to prevent humidity exposure.

Supplies Needed

Peptide Vial

Testoluten capsule bottle (20 mg per unit) containing dry oral biological extract.

Insulin Syringes (U-100)

Not required for oral capsule administration.

Bacteriostatic Water

Not required; encapsulated solid formulation needs no reconstitution.

Alcohol Swabs

Not required for non-injectable, oral bioregulator protocols.

Why researchers study it

Investigation of testes-derived signalling peptides on spermatogenic activity

Analysis of peptide bioregulator effects on Leydig cell androgen production

Evaluation of oral peptide bioavailability and tissue-specific trophic responses

Comparative screening against defined synthetic analogues such as Testagen

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Testoluten (Cytomax A-13) represents an orally administered peptide bioregulator derived from animal testicular tissues. Formulated within the framework of Khavinsonian gerontological science, it is classified as a parapharmaceutical extract rather than an isolated, synthetic chemical entity. The preparation is conventionally provided as encapsulated material targeting biological pathways associated with testicular cell function. Preclinical literature concerning male gonadal bioregulation largely stems from legacy research on related fractions like testilin or synthesized analogues like Testagen. These investigations suggest potential tissue-specific cellular interactions affecting spermatogenesis and local hormone dynamics, though Testoluten itself consists of a proprietary natural complex without Western regulatory approval. In contemporary laboratory protocols, Testoluten serves as a model for studying cellular signalling and tissue-derived trophic mechanisms in gonadal biology. Because it is administered exclusively in oral capsule form, standard peptide reconstitution and subcutaneous injection frameworks do not apply to this compound.

References

1.Khavinson, Neuroendocrinology Letters, 2002 — Peptides and Ageing
2.Boiko, Likars'ka Sprava, 1995 — Validation of prostatilen and testilin for treating male infertility
3.Khavinson et al., Advances in Gerontology, 2013 — Peptide bioregulators: a new class of geroprotectors
4.Khavinson et al., Molecules, 2020 — Peptides: prospects for use in the treatment of COVID-19